Good point.
The unique complexities and history of PPS makes it a tough call for outsiders without the technical / legal / scientific knowledge to understand the full implications of manufacturing generics coupled with drug registration requirements in different geographies and the use / approval of the drug for humans versus animals.
I did find this quite informative though - from the FiftyOneCapital 'Deep Dive' in March.
But there is a potential threat - note the use of "may not see any generic competition" in the last sentence.
Good point.The unique complexities and history of PPS makes it a...
-
- There are more pages in this discussion • 14 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
24.5¢ |
Change
-0.015(5.77%) |
Mkt cap ! $85.70M | |||
| Open | High | Low | Value | Volume |
| 26.0¢ | 26.0¢ | 24.5¢ | $265.4K | 1.050M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 130186 | 24.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 25.0¢ | 11571 | 1 |
View Market Depth
| Last trade - 16.10pm 31/07/2024 (20 minute delay) ? |
| PAR (ASX) Chart |